SAM
NBIX icon

Sectoral Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Sectoral Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$344K Sell
2,300
-375
-14% -$49.8K 0.28% 66
2025
Q4 		$379K Sell
2,675
-285
-10% -$41.3K 0.3% 62
2025
Q3 		$416K Hold
2,960
– – 0.26% 70
2025
Q2 		$372K Buy
2,960
+55
+2% +$6.31K 0.25% 75
2025
Q1 		$321K Sell
2,905
-8,895
-75% -$1.13M 0.25% 61
2024
Q4 		$1.61M Sell
11,800
-715
-6% -$88.4K 1.08% 25
2024
Q3 		$1.44M Buy
12,515
+8,580
+218% +$1.18M 0.85% 37
2024
Q2 		$542K Sell
3,935
-260
-6% -$35.7K 0.22% 63
2024
Q1 		$579K Sell
4,195
-250
-6% -$34.1K 0.23% 65
2023
Q4 		$586K Buy
4,445
+410
+10% +$47.2K 0.25% 70
2023
Q3 		$454K Buy
4,035
+575
+17% +$60.5K 0.09% 108
2023
Q2 		$326K Buy
3,460
+660
+24% +$64.5K 0.05% 112
2023
Q1 		$283K Hold
2,800
– – 0.05% 110
2022
Q4 		$334K Sell
2,800
-250
-8% -$29.3K 0.06% 110
2022
Q3 		$324K Hold
3,050
– – 0.06% 97
2022
Q2 		$297K Buy
+3,050
New +$281K 0.06% 101
2020
Q3 		– Sell
-14,100
Closed -$1.72M – 148
2020
Q2 		$1.72M Buy
+14,100
New +$1.56M 0.16% 83
2018
Q4 		– Sell
-6,803
Closed -$836K – 124
2018
Q3 		$836K Buy
+6,803
New +$772K 0.09% 74
2018
Q2 		– Sell
-111,402
Closed -$9.24M – 72
2018
Q1 		$9.24M Sell
111,402
-30,900
-22% -$2.61M 1.01% 38
2017
Q4 		$11M Sell
142,302
-90,300
-39% -$6.16M 1.38% 28
2017
Q3 		$14.3M Sell
232,602
-6,105
-3% -$322K 1.84% 28
2017
Q2 		$11M Sell
238,707
-612,312
-72% -$29.7M 1.2% 30
2017
Q1 		$36.8M Buy
851,019
+102,031
+14% +$4.37M 4.3% 4
2016
Q4 		$29M Sell
748,988
-53,991
-7% -$2.44M 3.21% 12
2016
Q3 		$40.7M Sell
802,979
-209,227
-21% -$10.4M 3.99% 7
2016
Q2 		$46M Sell
1,012,206
-637,757
-39% -$29.4M 4.75% 1
2016
Q1 		$65.3M Buy
1,649,963
+1,233,283
+296% +$48.9M 3.16% 11
2015
Q4 		$23.6M Buy
+416,680
New +$21.2M 1.01% 29

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sectoral Asset Management's NBIX Position: Q1 2026 in Review

Sectoral Asset Management reduced its Neurocrine Biosciences (NBIX) stake by 14% in Q1 2026, selling an estimated $49.8K and leaving 2,300 shares worth $344K. The position accounts for 0.28% of the portfolio, ranked #66.

Sectoral Asset Management first reported a position in NBIX in Q4 2015 and has held it in 28 quarters since. The position peaked at $65.3M in Q1 2016. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Sectoral Asset Management held 2,300 shares of Neurocrine Biosciences worth $344K as of Q1 2026.
  • Sectoral Asset Management sold 375 Neurocrine Biosciences shares in Q1 2026, an estimated $49.8K.
  • Neurocrine Biosciences made up 0.28% of Sectoral Asset Management's portfolio in Q1 2026, its #66 holding.
  • Sectoral Asset Management first reported a position in Neurocrine Biosciences in Q4 2015 and has held it in 28 quarters since.
  • Sectoral Asset Management's Neurocrine Biosciences position peaked at $65.3M in Q1 2016.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Sectoral Asset Management's 13F filing for Q1 2026, filed 15 May 2026.